Asia Pacific Microbiome Therapeutics Market Size & Outlook
Asia Pacific microbiome therapeutics market, 2018-2030 (US$M)
Related Markets
Asia Pacific microbiome therapeutics market highlights
- The Asia Pacific microbiome therapeutics market generated a revenue of USD 5.6 million in 2022.
- The market is expected to grow at a CAGR of 20.8% from 2023 to 2030.
- In terms of segment, c. difficile was the largest revenue generating application in 2022.
- C. difficile is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Japan is expected to register the highest CAGR from 2023 to 2030.
Asia Pacific data book summary
| Market revenue in 2022 | USD 5.6 million |
| Market revenue in 2030 | USD 25.3 million |
| Growth rate | 20.8% (CAGR from 2022 to 2030) |
| Largest segment | C. difficile |
| Fastest growing segment | C. difficile |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C. difficile, Crohns disease, Inflammatory Bowel Disease, Diabetes |
| Key market players worldwide | Finch Therapeutics Group Inc, Vedanta |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 5.9% of the global microbiome therapeutics market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 901.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Microbiome Therapeutics Market Scope
Microbiome Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific microbiome therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to microbiome therapeutics market will help companies and investors design strategic landscapes.
C. difficile was the largest segment with a revenue share of 83.93% in 2022. Horizon Databook has segmented the Asia Pacific microbiome therapeutics market based on c. difficile, crohns disease, inflammatory bowel disease, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
The Asia Pacific region is expected to grow at a substantial rate due to a number of factors such as increasing awareness about gut health, growing incidence of chronic diseases, increasing investment by key players, and government support for R&D in the field of microbiome.
In the Asia Pacific region, countries such as Japan, China, and South Korea are leading the market due to their well-established healthcare infrastructure, high investment in R&D, and the presence of major players in the microbiome industry.
Moreover, the Asia Pacific region is home to some of the fastest-growing economies in the world, and this is likely to result in an increase in the number of people who can afford advanced medical treatments, including microbiome-based therapies. This, in turn, is expected to further drive the growth of the Asia Pacific microbiome therapeutics market.
Reasons to subscribe to Asia Pacific microbiome therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific microbiome therapeutics market databook
-
Our clientele includes a mix of microbiome therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific microbiome therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific microbiome therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific microbiome therapeutics market size, by country, 2018-2030 (US$M)
Asia Pacific Microbiome Therapeutics Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
